GLI1 and acute myeloid leukemia: To summarize, this research focuses on using GLI-1 as a true prognostic tool in real AML patients as we noticed that most of the recent and previous experiments aimed at providing an additional treatment option through monitoring the effect of GLI-1 inhibitors on AML cell lines without developing a real technique to identify those patients who would truly benefit from this treatment option [21–25].